PIVKA-II

AcronymDefinition
PIVKA-IIProthrombin Induced by Vitamin K Absence or Antagonist-II
PIVKA-IIProtein Induced Vitamin K Absence or Antagonist II
References in periodicals archive ?
(3) Key words: (DCP) OR Key words: (decarboxy prothrombin) OR Key words: (des(gamma-carboxy)prothrombin) OR Key words: (des gamma-carboxy prothrombin) OR Key words: (des-gamma-carboxyprothrombin) OR Key words: (descarboxyprothrombin) OR Key words: (non-carboxylated factor II) OR Key words: (PIVKA II) OR Key words: (PIVKA-II) OR Key words: (protein induced by vitamin K absence or antagonist-II) OR Key words: (acarboxy prothrombin) OR Key words: (descarboxylated prothrombin) OR Key words: (protein induced by vitamin K absence or antagonists) OR Key words: (PIVKA) OR Key words: (prothrombin precursor) OR Key words: (Isoprothrombin) OR Key words: (des(y-carboxy)prothrombin) OR Key words: (des-y-carboxy prothrombin) OR Key words: (des-y-carboxyprothrombin)
(3) (DCP) or (descarboxyprothrombin) or (des gamma-carboxy prothrombin) or (des-gammacarboxy prothrombin) or (des-gamma-carboxyprothrombin) or (decarboxyprothrombin) or (non-carboxylated factor II) or (PIVKA II) or (PIVKA-II) or (protein induced by vitamin K absence or antagonist-II) or (acarboxyl prothrombin) or (decarboxylated prothrombin) or (protein induced by vitamin K absence or antagonists) or (PIVKA) or (prothrombin precursor) or (Isoprothrombin) or (des y-carboxy prothrombin) or (des-y-carboxy prothrombin) or (des-y-carboxyprothrombin)
Kim et al., "Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma," World Journal of Gastroenterology, vol.
Wang et al., "Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients," Tumor Biology, vol.
A total of 58% and 55% of patients had suboptimal vitK status (PIVKA-II values >3 ng/mL) pre- and post-LTX, respectively, despite routine recommendation for vitK supplementation (>1 mg/d).
(26,66) A study on hemodialysis patients subjected to varying doses of mk-7 intake resulted in a decrease in serum dp-ucMGP, ucOC and PIVKA-II levels significantly in the group treated with 360 microgram/day, but not at lower doses.
Keywords used for the search were as follows: (1) DCP: DCP, des-y-carboxy-prothrombin, des-gamma-carboxy-prothrombin, PIVKA-II, and protein induced by vitamin K absence; and (2) HCC: HCC, hepatocellular carcinoma, liver cell carcinoma, liver cancer, and hepatic cell carcinoma.
Jang et al., "Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP," Hepatogastroenterology, vol.
Shimauchi et al., "Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma," Journal of Gastroenterology, vol.
Jeon et al., "Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels," European Journal of Gastroenterology and Hepatolog, vol.
Thus, the renal tumor was controlled by repeated TAE, and the patient expressed low levels of serum PIVKA-II and AFP for at least one year after the emergent TAE.
CBC WBC 3.4 x [10.sup.3]/[micro]L RBC 3.3 x [10.sup.3]/[micro]L Hb 10.4 g/dL Hct 29.9 % MCV 90.6 fL Plt 159 x [10.sup.3]/[micro]L Reticulocyte 1.37 % Coagulation PT 81 % Tumor marker AFP 3.6 ng/mL PIVKA-II 18 mAU/mL HCV viral marker HCV RNA 6.14 logIU/mL HCV genotype 2b Biochemistry TP 7.2 g/dL Alb 4.2 g/dL Ferritin 98 ng/ml T-Bil 0.9 mg/dL D-Bil 0.1 U/L ID-Bil 0.8 U/L AST 37 U/L ALT 26 U/L LDH 227 U/L ALP 134 U/L [gamma]-GTP 13 U/L BUN 10.9 mg/dL Cr 0.63 mg/dL eGFR 69.1 ml/min/1.73 [m.sup.2] T-chol 199 mg/dL IL-28B genotype TT (rs8099917) ITPA C/A (rs7270101) FIB-4 index 3.38 Fibro scan * 4.3 Kpa (F0 level) CAP ** 206 dB/m (S0 level) Height 148 cm Weight 49.8 kg * Transient elastography (Fibroscan [R]).